Cancer drugs: reimbursement incentives influence prescribing practices

Cancer doctors who administer chemotherapy remedys intravenously in their offices have been reaping considerable profits from these medicines Unique among other physicians, these oncologists are in a faculty of perception running their own pharmacies. The oncologists purchase the cancer drugs from the physic companies who give them generous discounts; they bill their patients for the medicines administered intravenously; and they are reimbursed through the government programs and insurance companies at rates that oftentimes far exceed what they actually paid for the drugs

Does this obvious conflict of interest encourage promiscuous use of chemotherapy? A of recent origin study, published in the March/April 2006 issue of the academic journal Health Affairs, base that the reimbursement system did not strike one as being to influence the decision to prescribe chemotherapy in the first place, on the other hand it did appear to encourage oncologists to use the greatest in quantity expensive drugs. This is to be paid to the fact that the greatest in quantity costly drugs came with the largest discounts, and therefore the greatest in quantity generous profit margins for the doctors.

This inquiry led by Dr. Mireille Jacobson, direct the eyeed solely at the effect of reimbursement upon the use of chemotherapy for 9357 advanced cancer patients registered in Medicare. All had metastatic lung breast, colorectal or other gastrointestinal cancer between 1995 and 1998 These cancers show over 60% of cancer deaths in North America. Jacobson and colleagues wrote that they confined their research to the Medicare claims made upon behalf of people with metastasized cancer (disease that has spread to other organs) because these tribe have a relatively short wait fored survival time, regardless of treatment.

The reimbursement combination of parts to form a whole had long allowed oncologists to purchase drugs at what is called the average wholesale price, also known as the "suggest retail price" or "sticker price." A law dating back to the Reagan Administration, however, obstructed Medicare from learning exactly by what mode large were the discounts doctors received from the medicine companies. The system was finally overhauled as of this year when the Medicare Prescription medicine Improvement, and Modernization Act went into result Much of the credit for this lengthy overdue change goes to a Congressional hearing that revealed Medicare payments for part B-cover physics were often far in exces of what oncologists had paid for the remedys (Medicare part B-covered drugs consigns to all drugs that cannot be self-administered.)

The Congressional hearing l to a 2001 report by dint of the U.S. General Accountability Office entitled, "Medicare: Payments for overspreaded Outpatient Drugs Exceed Providers' Cost" It fix that the discounts varied by means of drug, and some could be as high as 65% and 85% The report acknowledged the oncologists' defense which is that the extra coin is needed to cover the require to be paid [i]or[/i] undergone of administering the drugs in their offices and other services tendered their patients, such as nutrition counseling.

Jacobson and colleagues wrote that the fresh legislation has changed the configuration of the reimbursement system, in the way that that physician payment is now based upon the "manufacturers' average sales price plus 6% and an administrative fee" The sales price is broadly representative of the prices paid for cancer remedys in the U.S. Medicare, for example, is forbidden through law to negotiate discounts for its enrollee on the contrary the Veterans Administration hospitals has been doing just that for years. with equal reason are many private insurers.

Given these differing pricing combination of parts to form a wholes Jacobson and colleagues contend that it is still worth exploring the relationship between various reimbursement incentives and prescribing patterns. "Since reimbursement rates for chemotherapy vary greatly within the private market, with many insurance companies basing their rates upon the average wholesale price, this research could lay open treatment distortions that persist in the private market."

This application of mind was funded by the U Agency for Healthcare Research and Quality.

Five-Year HealthFacts Index Offer

For a five-year index of all issues of HealthFacts from 2001 from one side 2005, send a check for $500 to Center for Medical Consumer 239 Thompson way New York, New York 10012

COPYRIGHT 2006 Center for Medical Consumer Inc.

COPYRIGHT 2006 Gale Group